~" Antitumor activity against intracranial malignant teratoma by combination chemotherapy with cisplatin and etoposide was evaluated in experimental and clinical studies. A human teratoma cell line (Tera 2) was exposed in vitro to cisplatin and/or etoposide, after which cell growth inhibition and alterations of deoxyribonucleic acid (DNA) histograms were observed. The results indicated that a synergistic cytotoxic effect was achieved by use of both agents in combination. Four cases of recurrent intracranial germ-cell tumor (three malignant teratomas and one germinoma) were treated with cisplatin and etoposide. With this combination therapy, regression of the tumor was observed in all four cases (three complete and one partial), for a total response rate of 100%. During a follow-up period of 9 to 22 months, no recurrence or progression has been noted in three of these cases.
A
MONG intracranial germ-cell tumors, germinoma and mature teratoma are curable by irradiation and surgical treatment, respectively)1.14 However, malignant teratomas such as embryonal carcinoma, yolk-sac tumor, choriocarcinoma, or combinations of these are refractory to this treatment, and investigators have directed their attention to adjuvant chemotherapy. 7'8'13:4 It has been shown that combined chemotherapy with cisplatin (cis-diamminedichloroplatinum (II)), vinblastine, and bleomycin (PVB therapy) is effective as initial treatment for intracranial malignant teratomas 13,1~ as well as for gonadal germcell tumors. 7'8 The overall response rate is reported to be more than 90%; however, all cases relapsed within 2 years, 1~ and no response was obtained by repeating the same regimen at the time of recurrence.
This report involves a new chemotherapy combination with cisplatin and etoposide (4-demethylepipodophyllotoxin-/~-D-ethylidene glucopyranoside) for treatment of refractory or relapsed intracranial germ-cell tumors. This chemotherapy method is proposed on the basis of experimental and clinical studies presented here.
Experimental Study

Materials and Methods
Two tumor cell lines, human malignant teratoma derived from thymus (Tera 2) and human glioblastoma multiforme (U-251 MG), were cultured and prepared in complete minimum essential medium.* Tumor cell density was adjusted to 2 • 10 4 cells/ml for Tera 2 and 1 • 10 4 cells/ml for U-251 MG, and 1 ml of the cell suspension was plated in each well of Falcon microplates.
When tumor cells began to show logarithmic growth with incubation at 37"C, they were exposed for 3 days to a single therapeutic agent or to a combination of two drugs at different concentrations in the medium by adding saline-dissolved agents as follows: cisplatin, 0.1 or 0.01 #g/ml; pepleomycin ((3-((S)-1-phenylethyl) aminopropyl) aminobleomycin sulfate), 0.1 or 0.01 #g/ml; ACNU ( 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-* Tera 2 was established at Memorial Sloan-Kettering Cancer Center, New York, New York; U-251 MG was established at the University of Uppsala, Uppsala, Sweden. 5  5  20  5  70  80  70  30  Hu IFN-fl, 100 IU/ml  50  5  10  10  40  20  10  5  80  80  70  50  Hu IFN-fl, 1000 IU/ml  50  20  10  30  50  20  10  10  80  90  80  60  etoposide, 0.005 ~g/ml  40  40  10  10  20  20  10  5  80  80  80  70  etoposide, 0.05 pg/ml  80  80  80  70  90  95  95  90  95  > 99  > 99  > 99  pepleomycin, 0.01 ttg/ml  50  40  30  30  50  40  30  10  80  90  90 
Results
Inhibition of Tumor Cell Growth. The inhibition rate was calculated from the ratio of viable tumor cells of treated wells to those of the untreated control subtracted from 1 and multiplied by 100 ( Table 1 ). The cytotoxic effect in each experimental group reached a maximum level at 5 to 8 days after treatment, but decreased thereafter. It was also noted that the cytotoxic activity was increased and prolonged when a combination of two drugs was used. When only a single drug was used, a cytotoxic effect of more than 60% was found in Tera 2 (malignant teratoma) cells treated with cisplatin (0.1 tzg/ml), etoposide (0.05 #g/ml), or pepleomycin (0.1 tzg/ml). In malignant glioma (U-251 MG) cells, a similar effect was observed with cisplatin (0.1 #g/ml) or Hu INF-fl (102 or 103 IU/ml). All combinations of two drugs that included a higher concentration of cisplatin (0.1 t~g/ml) produced a cytotoxic effect of more than 60% in both cell lines. With a lower concentration of cisplatin (0.01 t~g/ml), cytotoxic effects were observed when cisplatin was used in combination with etoposide (0.05 t,g/ml) and pepleomycin (0.1 #g/ml) for Tera 2 cells, and with Hu INF-fl (102 or 103 IU/ml) and etoposide (0.05 tzg/ml) for U-251 MG cells. No inhibitory effect was found in either control group.
When cisplatin or etoposide was used alone in either concentration only a cytotoxic effect was noted for both cell lines, but these drugs used in combination had a cytocidal effect (presumed to be the result of a synergistic mechanism) on Tera 2 cells.
Analysis of DNA Histograms by Flow Cytometry.
The effects on Tera 2 cells of treatment with cisplatin and etoposide, singly and in combination, were determined by flow cytometry. The DNA histogram after 24 hours showed massive accumulation of cells in the later S-phase with use of etoposide alone, and this accumulation was increased by the combination treatment. The DNA histogram after 48 hours of use of either drug alone showed recovery to a normal pattern, but after the combination treatment a tendency toward accumulation of cells in the G2/M phase was observed (Fig. 1) .
Clinical Study
Therapeutic Schedule
The therapeutic schedule is presented in Fig. 2 days (one course). Two or three courses of treatment, at intervals of 4 weeks, were usually administered. The effects of treatment were evaluated by repeated computerized tomography (CT) scans, neurological signs, and/or tumor markers. A "complete response" indicates diminished visible lesion, and a "partial response" indicates size of lesions decreased by more than 50% on CT.
Results of Treatment
Four cases of recurrent intracranial germ-cell tumor were treated by the regimen described above ( Table 2 ). The histological diagnoses at the time of initial treatment were malignant teratoma (three patients) and germinoma (one patient). Initially, the patients had undergone surgery and radiation therapy, or chemotherapy with the PVB regimen, or a combination of these. Three patients had achieved complete response and one exhibited partial response until relapse or progression at 16, 20, 24, and 89 months. Combination treatment with cisplatin and etoposide was administered to these patients at the time of relapse, resulting in complete response in three cases and partial response in one case, for an overall response rate of 100%. During the follow-up period of 9 to 22 months one patient died, but otherwise there was no repeat relapse after the treatment (mean follow-up period 16 months). The three surviving patients are in good condition and are living essentially normal lives. The patient who died (Case 3) had shown complete remission after one course of therapy, but therapy was then stopped; in this patient the drugs were not used simultaneously.
Case Reports Case 1. This 15-year-old girl was diagnosed as having a suprasellar tumor, with an increased serum level of human chorionic gonadotropin (HCG: 160 IU/ml), at her first admission in 1984. At craniotomy, biopsy of the tumor revealed germinoma with a component of choriocarcinoma. One course of chemotherapy with the PVB regimen and whole-skull radiation of 40 Gy were administered postoperatively. The patient showed improvement of clinical signs, with a normalized serum HCG level, and was discharged. After 16 months of remission, she was found to have increased serum HCG and alpha-fetoprotein (AFP) levels. ACT scan revealed an enlarged suprasellar mass. The patient was given combined cisplatin and etoposide therapy at the time of readmission in August, 1986. Serum levels of HCG and AFP returned to normal after completion of two courses of chemotherapy. The suprasellar mass showed a decreased size on CT (a partial response), and the patient returned to school 17 months after the treatment. (Fig. 3A) .
The patient received two courses of c o m b i n e d treatm e n t with cisplatin and etoposide, followed by wholeskull irradiation of 40 Gy. T h e serum A F P , H C G , and C E A levels returned to n o r m a l , and the t u m o r mass entirely disappeared (a c o m p l e t e response) on CT ( Fig.   3B and C) . A t present, 22 m o n t h s after c o m b i n e d c h e m o t h e r a p y , the patient has r e t u r n e d to school with m i n o r n e u r o l o g i c a l deficits.
Case 3. T h i s 15-year-old girl s h o w e d high s e r u m H C G (4.0 m l U / m l ) a n d cerebrospinal fluid H C G (23 m l U / m l ) levels at the t i m e of presentation. A C T scan revealed an e n h a n c e d mass in the right t h a l a m i c region. W i t h a p r e s u m p t i v e diagnosis o f germ-cell t u m o r , focal i r r a d i a t i o n o f 50 G y was a d m i n i s t e r e d to the t u m o r
site, a n d the t u m o r c o m p l e t e l y disappeared. O n e y e a r later, a r e c u r r e n t mass was found in the f o u r t h ventricle, which also d i s a p p e a r e d after irradiation o f 30 G y to the posterior fossa followed b y 15 G y to the spine. A n o t h e r recurrence was f o u n d in the p e r i v e n t r i c u l a r region o f the lateral ventricles 10 m o n t h s later. Cisplatin was given for 5 successive days, followed b y e t o p o s i d e for a n o t h e r 5 days, a n d the t u m o r again entirely disappeared (a c o m p l e t e response) on CT. H o w e v e r , 6 m o n t h s later the patient had a recurrent lesion at the 9 m o s * G = germinoma; C = choriocarcinoma; E = embryonal carcinoma; PVB = cisplatin + vinblastine + bleomycin; PR = partial response; CR = complete response, PE = cisplatin + etoposide in combination; P + E = cisplatin and etoposide separately. same site. The previous regimen was repeated, but the response was only partial with the tumor decreasing in size. She died 6 months later as a result of pneumonia and tumor progression.
Case 4. This 36-year-old man complained of nausea, dizziness, and double vision in June, 1979. Neurological examination revealed right hemiparesis, papilledema, cerebellar signs, and a right cranial-nerve sign. ACT scan showed an enhanced mass involving the pineal body and fourth ventricle, and the patient underwent partial removal of the fourth ventricle mass by suboccipital craniectomy. The pathological diagnosis was germinoma. Irradiation to the entire central nervous system (CNS) of 40 Gy was given after a ventriculoperitoneal shunt had been placed. A complete response was obtained, and the patient was discharged without neurological deficits.
After 7 89 years, the patient showed signs of duodenal obstruction and was admitted to the general surgery service of another hospital. Abdominal CT scanning revealed a large intra-abdominal mass. Laparotomy disclosed a huge retroperitoneal mass, diagnosed on biopsy as a germinoma. After the patient was referred to the department of neurosurgery, three courses of chemotherapy with cisplatin and etoposide were administered. The tumor gradually disappeared and complete remission has been maintained for 9 months up to the present time.
Discussion
Of the varieties of intracranial germ-cell tumors, germinoma and mature teratomas are curable by radiation therapy and surgery, respectively. TM However, the prognosis for malignant teratoma is poor] 6 and mean survival time has been approximately 2 years. ~~ The antitumor effects of cisplatin were first reported by Rosenberg and VanCamp ~7 in 1970 . Its effectiveness has been demonstrated for solid tumors such as testicular tumor, 8 genitourinary tumor, ~5 and various other malignant tumors. 9'18 Recently, the effectiveness of cisplatin alone or in combination therapy, such as the PVB regimen, 7 has been confirmed not only in testicular tumors ~9 but also in intracranial malignant teratomas. lO,13,14 The initial response rate was 100% in l0 cases of malignant intracranial teratomas in a series reported by us. ~~ However, there was no response in cases of recurrent tumors, and all patients died within 2 years.
Etoposide is a semisynthetic derivative of podophyllotoxin and has been effective as an anticancer drug for small-cell carcinoma of the lung, 1 malignant lymphoma, 5 leukemia, and/or testicular tumors. 4 Single or combination chemotherapy with etoposide 2,3,~z has been investigated in clinical trials. The present in vitro study has demonstrated that the combination of cisplatin and etoposide showed the highest cytotoxic, synergistic effect for Tera 2 cells. This effect was also confirmed by DNA analysis. On the basis of the exper-imental study, a combined regimen with cisplatin and etoposide for malignant teratomas has been proposed. Although the concentrations of both drugs used in the in vitro study are not immediately applicable to clinical use, simultaneous use of both drugs may be important and may induce synergistic effects for killing tumor cells.
In the clinical trial of four cases with recurrent germcell tumors, it was found that combination therapy with cisplatin and etoposide was effective in tumors recurring after other types of treatment. A complete response was obtained in three patients and a partial response in one. Although one patient with a complete response died 13 months later as a result of tumor progression, the average duration of remission among surviving patients was 16 months at the time of writing.
It can be postulated that combination therapy with cisplatin and etoposide is effective not only for initial treatment but also for recurrent or refractory intracranial malignant teratomas previously treated with cisplatin. Although germinoma is curable by radiation therapy, brain atrophy and hormonal disturbances frequently follow irradiation to the whole CNS. 6 Avoidance of such side effects may be possible with the use of chemotherapy, either alone or in combination with irradiation, to treat germ-cell tumors.
